Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals3 Feb 2019
Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.
Sartorius has joined NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals headquartered in Newark, Delaware, USA.
The Institute, launched in 2017, is a public-private partnership and has an extensive network of academic and industry partners within the United States. Among the 115 associated members are 71 academic institutions, research laboratories, non-profit organizations and 44 companies – ranging from startups, small, medium and large companies. In addition, NIIMBL also engages several federal agencies. NIIMBL’s multi-pronged mission includes the following: accelerate biopharmaceutical manufacturing innovations, support the development of standards, enable more efficient and rapid manufacturing capabilities and establish an international, leading workforce to fundamentally strengthen the U.S. biopharmaceutical industry.
Recently NIIMBL expanded its membership offerings, allowing technology providers wider access to participation. Sartorius has joined the organization through this new affiliate membership program that permits the company to actively support the NIIMBL community activities. Furthermore, the program gives Sartorius the opportunity to influence the organization’s portfolio of existing innovation projects, give feedback to the review of new project proposals and directly sponsor one of the upcoming projects.
As a new member, Sartorius will initially learn about the NIIMBL technology project portfolio and seek opportunities to provide expertise on innovative ideas and solutions, including the application of existing technologies from its broad and unique product and technology portfolio. Examples such as single-use sensor technologies along with process analytical tools (PAT), data analytics and innovative solutions for next-generation bioprocessing will be among the key technologies Sartorius will contribute to these projects.
“We are very pleased that Sartorius is now a member of the NIIMBL organization and are excited about being able to collaborate with its members,” stated David J. Pollard, who heads the Advanced Materials & Processing unit at Sartorius Corporate Research. “I am convinced that with our access to the combined expertise of the NIIMBL community, we will be able to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry. As a leading partner of this industry, I see many highly interesting synergies that will result from the interface between Sartorius and NIIMBL members,” added Pollard.
”Sartorius’ extensive knowledge of biopharmaceutical process development equipment will be valuable to the community as we develop innovative manufacturing technologies,” stated Kelvin Lee, NIIMBL Institute Director.
Leaf Expression Systems launches first line of Hypertrans research products
13 Jun 2019
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Combining IT and OT software to solve manufacturing’s most frequent challenges
11 Jun 2019
PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.Read more
Sphere Fluidics secures funding to support its single cell analysis system
11 Jun 2019
Funding will also be used to further expand operations in the UK and US.Read more
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma
6 Jun 2019
Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.Read more
Cambrex completes new process and analytical development facility at Sweden manufacturing site
5 Jun 2019
The process technology laboratories will include new capabilities in the scaling up of potent molecules requiring containment.Read more
Sterling pilot plant facility expansion up and running
4 Jun 2019
Additional three new reactor trains will help the CDMO to meet growing market demand for smaller API batch sizes.Read more
Lilly gets its hands on non-opioid pain asset
4 Jun 2019
Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.Read more
Updated clinical trial simulation software saves time and money
3 Jun 2019
One customer saves $25m and 3 years' development time in their clinical development strategy.Read more
Ampersand Capital Partners to acquire Vibalogics
3 Jun 2019
Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation